Woman, 20, Diagnosed With Cancer After STD Fears Stopped Her Seeking Help

Author: BY AATIF SULLEYMAN Date: 2/15/2022 Source: www.newsweek.com Ayoung woman who was diagnosed with cancer said she delayed seeing a doctor for months because she was "embarrassed" that she might have had a sexually transmitted disease (STD). Olivia Wallace, from Sunderland in northeastern England, had been experiencing issues with her tongue for seven months before her father eventually took her to see a doctor. She was diagnosed with stage 4 tongue cancer, which had spread to her lymph nodes. Some 8,001 people aged between 20 and 24 years old were diagnosed with cancer in the U.S. in 2018 (the most recent year for which data exists), according to the U.S. Centers for Disease Control and Prevention. She had first noticed a lump on her tongue in 2015, but initially thought that it was a recurring ulcer. However, when the lump continued to expand and became increasingly sensitive to the touch, to the extent that Wallace would be in pain whenever she tried to eat anything, she became convinced that she had contracted an STD, which is also known as a sexually transmitted infection (STI). "Luckily for me, my dad had taken me to the doctors and he was in the waiting room as I thought it was an STI and I was embarrassed," Wallace told Chronicle Live. "There is a stigma attached to young women and STIs, so that deterred me from getting checked out even though it was frightening me." Now aged 26, Wallace is cancer free. However, she fears that would [...]

2022-02-16T07:55:49-07:00February, 2022|OCF In The News, Oral Cancer News|

Dental Professionals Should Remember the HPV Vaccine Too

Source: Dentistry Today Date: April 13th, 2021 Author: Jo-Anne Jones We live in a viral world as we patiently await the end of the COVID-19 pandemic. Many people already have chosen to be vaccinated to protect themselves from getting the virus, or, at the very least, minimize its severity. The harsh nature of the pandemic has led to expediency in developing the vaccine, which has not been typical, historically speaking. While the COVID-19 vaccine took less than a year to develop, the mumps vaccine took four years. The polio vaccine took 13 years. The human papillomavirus (HPV), flu, and chicken pox vaccines took 17, 27, and 28 years, respectively. Looking back in the annals of history, we have the remarkable work of Edward Jenner to thank for his development of the first vaccine. His work involved deliberately infecting a human being with a mild dose of smallpox. His rigorous trials were controlled, repeatable, and documented in his 1798 publication, “An Inquiry Into the Causes and Effects of the Variolæ Vaccinæ.” Jenner devoted the remainder of his life advocating for the safe and effective administration of the vaccine. In 1972, routine smallpox vaccination ended in the United States, followed by the World Health Organization declaring the disease’s elimination in 1980. Another such vaccine victory is the polio vaccine, which was first available in the United States in 1955. Thanks to its widespread use, the United States has been polio-free since 1979. And while the United States government has said that dentists [...]

2021-04-13T12:57:09-07:00April, 2021|OCF In The News|

How the ADA Oral Cancer Policy Amendment Will Affect Your Practice

Source: Dentistry Today Date: November 29th, 2019 Author: Jo-Anne Jones The ADA recently announced an expansion to its policy on oral cancer detection recommending that dentists and dental hygienists perform routine examinations for oral cancer includingoropharyngeal cancer for all patients. Passed by the ADA House of Delegates in September, this change was brought about to align with concerns from the Centers for Disease Control and Prevention (CDC) over the escalating numbers of diagnosed cases of oropharyngeal cancer linked to the human papillomavirus (HPV). While HPV-related oropharyngeal cancer has risen by 225% over the past two decades, oral cancer linked to the historical etiologic pathways of tobacco and alcohol use has declined by 50%. The ADA’s policy also aligns with support for the HPV vaccine, as 70% of oropharyngeal cancers in the United States are related to HPV, according to the CDC. Dentists and dental hygienists play a critical role in opportunistic screening on all adult patients despite whether they possess the historical risk factors of using tobacco products or alcohol. There is a distinct knowledge gap in today’s population to fully understand that a non-smoker and non-drinker may in fact be at risk for oral and oropharyngeal cancer due to HPV. It is our responsibility to educate our dental patients about all of the risk factors that exist for both oral and oropharyngeal cancer. Now more than ever, it is critically important to extend our screening practices, both visual and tactile, to every adult in the practice on an annual basis. [...]

2019-12-03T17:49:17-07:00December, 2019|OCF In The News, Oral Cancer News|

Prevalence of Oral HPV Infection Declines in Unvaccinated Individuals

Source: Infectious Disease Advisor Date: September 30th, 2019 Author: Zahra Masoud Oral human papillomavirus (HPV) prevalence has decreased in unvaccinated men, possibly as a result of herd protection, but the incidence of such infection has remained unchanged in unvaccinated women from 2009 to 2016 in the United States, according to a study published in the Journal of the American Medical Association. Since 2011 for women and 2006 for men, prophylactic HPV vaccination for prevention of anogenital HPV infection has been recommended for routine use in the United States. Previous studies have demonstrated that this vaccine has high efficacy in reducing the prevalence of oral HPV infection. However, the vaccine is not indicated to prevent oral HPV infection or oropharyngeal cancers because there are few results from randomized trials. Further, there has been a lack of surveillance studies reporting on herd protection against oral HPV infection, which is defined as a form of indirect protection from infectious diseases that occurs when a large percentage of the population has become immune/vaccinated, thereby providing protection for individuals who are not immune/not vaccinated. Therefore, this study investigated evidence for herd protection against oral HPV infection in unvaccinated men and women in the United States using temporal comparisons of oral HPV prevalence for 4 vaccine types and 33 non-vaccine types. This study was conducted across 4 cycles (from 2009 to 2016) of the National Health and Nutrition Examination Survey (NHANES), using a cross-sectional, stratified, multistage probability sample of the civilian population in the United States. For the examination [...]

2019-10-01T16:15:25-07:00October, 2019|OCF In The News|

No De-escalation of Therapy for HPV+ Throat Cancer

Source: www.medscape.com Author: Alexander M. Castellino, PhD Another trial has shown that de-escalating therapy does not work in patients with good prognosis human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma or throat cancers. Results from the De-ESCALaTE HPV study show that using the targeted drug cetuximab with radiotherapy does not improve side effects and, more importantly, has worse survival compared with the standard of care — chemotherapy with cisplatin and radiotherapy. The finding echoes the results from the US National Cancer Institute's Radiation Therapy Oncology Group (RTOG) 1016 trial, the top-line results of which were released earlier this year, and details of which were presented this week at the American Society of Radiation Oncology (ASTRO) 2018 meeting. "Do not change your clinical practice of using cisplatin with radiotherapy in these patients," cautioned Hisham Mehanna, MBChB, PhD, chair of head and neck surgery at the University of Birmingham, United Kingdom, and lead investigator of the De-ESCALaTe study. He presented the results during a presidential session here at the European Society for Medical Oncology (ESMO) 2018 Congress (abstract LBA9). "Cetuximab did not cause less toxicity and resulted in worse overall survival and more cancer recurrence than cisplatin. This was a surprise — we thought it would lead to the same survival rates but better toxicity. Patients with throat cancer who are HPV+ should be given cisplatin, and not cetuximab, where possible," Mehanna said in a statement. Hope for Fewer Side Effects Cetuximab with radiation is already approved by the US Food and Drug [...]

2018-10-28T11:45:33-07:00October, 2018|OCF In The News, Oral Cancer News|

OCF’s Tobacco Cessation Spokesperson and Bradley Cooper’s Stunt Double Rides in Pendleton

You won’t find Cody Kiser at this year’s NFR, but you will find him working as a stuntman in the 2014 blockerbuster hit “American Sniper” starring Bradley Cooper. The biographical war drama was directed by Clint Eastwood, and told the story of U.S. Navy Seal Chris Kyle. Kiser, who rode Saturn Rocket for a 75.5-point score Friday at the Pendleton Round-Up, stepped in for Bradley during the scene that shows Kyle riding broncs during his rodeo days before he joined the Navy. “That was the coolest thing I have ever done,” Kiser said. “I got to hang out for a day with Clint Eastwood and Bradley Cooper. Clint told me I looked a lot like Bradley. They said they wished they had me for the whole movie.” A friend of Kiser’s who does stunt work in California put Kiser in touch with the people from the movie. “They needed a bareback rider who had a certain look,” he said. “They had me and a saddle bronc rider, but he couldn’t ride bareback very well, so the job was mine.” Kiser, 27, said he was living in Texas near where Kyle was shot in 2013, and that he had a friend working at the Rough Creek Ranch-Lodge in Erath County, Texas, where Kyle was shot. “It’s such a small world,” he said. Kiser earned a nice paycheck for his work, but said playing Kyle, even in a stunt role, was an honor. “To be a part of that was unreal,” he [...]

2018-09-28T09:37:18-07:00September, 2018|OCF In The News|

How ablation destroys cancer to prolong lives

Source: The Guardian Author: David Cox Seven years ago, when Heather Hall was informed by her oncologist that her kidney cancer had spread to the liver, she initially assumed she had just months to live. “I’d been on chemotherapy for a while, but they’d done a CT scan and found three new tumours,” she says. “But they then said that, because the tumours were relatively small, they could try to lengthen my prognosis by removing them with ablation.” Hall underwent a course of microwave ablation, a minimally invasive treatment where surgeons use hollow needles to deliver intense, focused doses of radiation to heat each tumour until it is destroyed. While ablation technologies – they also commonly include radiofrequency ablation and cryoablation, which destroys tumours using intense cold – are not tackling the underlying cause of the disease, their impact can be enormous as they relieve pain and often prolong survival for many years, all at a low cost. Studies based on data gathered over the past 10 years show an increasing number of cases of terminally ill patients who have lived for well over a decade after being treated with repeated ablations. Hall’s treatment was successful, but two years later, another two tumours had appeared in her liver, in different locations. Once again they were removed with microwave ablation. Over the past seven years, she has had four separate treatments. “There’s some pain in the immediate aftermath and I’ve felt quite ill for a week afterwards,” she says. “But it [...]

2018-08-06T10:43:25-07:00August, 2018|OCF In The News|

HPV: The gender-neutral killer in need of prevention among men

Source: CNN Author: Dominic Rech In July 2014, Phil Rech, then 59, was diagnosed with tonsil cancer. "I had got a lump in my neck. I had the tonsils out, and within the next few days, I was having radical neck dissection," he said. "Then I had six weeks of intensive, targeted radiotherapy. The burning effect towards the end of the treatment became very painful." The therapy involved a radiotherapy mask, molded to the shape of his face, that went over his head as radiotherapy was beamed in, targeting the cancer. The discovery of his cancer not only startled him, it startled everyone who knew him. Phil is my dad, and to our family, he had always been healthy: He doesn't smoke, he rarely drinks alcohol, and he generally stays fairly fit. But that's not how cancer works. At the time of the diagnosis, Phil didn't question how or what could have caused his cancer, as he focused on getting better. Like many men in the UK and around the world, he wasn't aware of a group of viruses that were a threat, human papillomavirus or HPV, which were eventually connected to his cancer. "To discover it was linked to HPV was a massive shock," he said. "There was a lot of speculation over what could have caused it. To discover it was that, was certainly a surprise. I didn't really know it was a threat to me." A cancerous virus HPV is a group of 150 related viruses that [...]

2018-07-28T15:15:04-07:00July, 2018|OCF In The News|

Health Insurers Are Vacuuming Up Details About You — And It Could Raise Your Rates

Source: National Public Radio Author: Marshall Allen To an outsider, the fancy booths at a June health insurance industry gathering in San Diego, Calif., aren't very compelling: a handful of companies pitching "lifestyle" data and salespeople touting jargony phrases like "social determinants of health." But dig deeper and the implications of what they're selling might give many patients pause: a future in which everything you do — the things you buy, the food you eat, the time you spend watching TV — may help determine how much you pay for health insurance. With little public scrutiny, the health insurance industry has joined forces with data brokers to vacuum up personal details about hundreds of millions of Americans, including, odds are, many readers of this story. The companies are tracking your race, education level, TV habits, marital status, net worth. They're collecting what you post on social media, whether you're behind on your bills, what you order online. Then they feed this information into complicated computer algorithms that spit out predictions about how much your health care could cost them. Are you a woman who recently changed your name? You could be newly married and have a pricey pregnancy pending. Or maybe you're stressed and anxious from a recent divorce. That, too, the computer models predict, may run up your medical bills. Are you a woman who has purchased plus-size clothing? You're considered at risk of depression. Mental health care can be expensive. Low-income and a minority? That means, the data [...]

2018-07-17T09:40:59-07:00July, 2018|OCF In The News|

Cancer: Can testosterone improve patients’ quality of life?

Source: Medical News Today Author: Maria Cohut Cachexia is a condition characterized by loss of body mass — including muscular atrophy — that is usually accompanied by severe weakness and fatigue. Many people who go through cancer experience this. Studies have noted that "[a]pproximately half of all patients with cancer experience cachexia," severely impairing their quality of life. It appears to be "responsible for the death of 22 [percent] of cancer patients." What exactly causes this condition — which appears in some patients but not in others — remains unclear, and options to manage and address it are scarce. But recently, researchers from the University of Texas Medical Branch in Galveston — led by Dr. Melinda Sheffield-Moore, from the Department of Health and Kinesiology — have been investigating the potential of administering testosterone in addition to chemotherapy in order to ameliorate the impact of cachexia. "We hoped to demonstrate these [cancer] patients [who received testosterone treatment] would go from not feeling well enough to even get out of bed to at least being able to have some basic quality of life that allows them to take care of themselves and receive therapy." Dr. Melinda Sheffield-Moore The researchers' findings — now published in the Journal of Cachexia, Sarcopenia and Muscle — confirm that administering testosterone to individuals experiencing cachexia can, in fact, improve their quality of life to some extent, by restoring some independence of movement. Adjuvant testosterone shows promise The most widely used approach to manage cachexia is special nutrition treatments, but [...]

2018-07-17T09:30:54-07:00July, 2018|OCF In The News|
Go to Top